Why is Novolog (Pharm UP 1966) Ltd. ?
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Net Sales has grown by an annual rate of 14.37% and Operating profit at -7.02% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Below par performance in long term as well as near term
- Along with generating -28.70% returns in the last 1 year, the stock has also underperformed Israel TA-100 in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Novolog (Pharm UP 1966) Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Novolog (Pharm UP 1966) Ltd.
-27.22%
-0.54
33.32%
Israel TA-100
49.53%
2.91
16.81%
Quality key factors
Factor
Value
Sales Growth (5y)
14.37%
EBIT Growth (5y)
-7.02%
EBIT to Interest (avg)
5.13
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
4.47
Tax Ratio
30.00%
Dividend Payout Ratio
63.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.94%
ROE (avg)
7.14%
Valuation Key Factors 
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
1.73
EV to EBIT
10.83
EV to EBITDA
3.78
EV to Capital Employed
2.50
EV to Sales
0.22
PEG Ratio
0.14
Dividend Yield
307.73%
ROCE (Latest)
23.04%
ROE (Latest)
5.43%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend






